Alpha 2.0
Login Register
» Authors » Stacie Hudgens

Stacie Hudgens

Explore the profile of Stacie Hudgens including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 61
Citations 907
Followers 0
Related Specialties
Pharmacology
Oncology
Public Health
Top 10 Co-Authors
Lysbeth Floden
Tara Symonds
Jennifer L Beaumont
Louise Newton
David Cella
Christina Guldberg
Sonya Eremenco
Mazen M Dimachkie
Benjamin Banderas
Elke Hunsche
Published In
Value Health
J Patient Rep Outcomes
Lancet Oncol
Clin Ther
Qual Life Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
Armstrong A, Augustin M, Beaumont J, Pham T, Hudgens S, Gordon K, et al.
Dermatol Ther (Heidelb) . 2025 Mar; PMID: 40048065
No abstract available.
2.
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
Armstrong A, Augustin M, Beaumont J, Pham T, Hudgens S, Gordon K, et al.
Dermatol Ther (Heidelb) . 2024 Jul; 14(8):2235-2248. PMID: 39080153
Introduction: Deucravacitinib, a novel, oral, selective allosteric tyrosine kinase 2 inhibitor, demonstrated superiority versus placebo and apremilast in the POETYK PSO-1 and PSO-2 studies. We describe patient-reported outcomes with deucravacitinib...
3.
Measurement properties of the Inclusion Body Myositis Functional Rating Scale
Salam S, Symonds T, Doll H, Rousell S, Randall J, Lloyd-Price L, et al.
J Neurol Neurosurg Psychiatry . 2024 Jul; 96(2):122-131. PMID: 38960586
Objectives: To evaluate the validity, reliability, responsiveness and meaningful change threshold of the Inclusion Body Myositis (IBM) Functional Rating Scale (FRS). Methods: Data from a large 20-month multicentre, randomised, double-blind,...
4.
Development of a Novel Patient-Reported Outcome Measure to Assess Symptoms and Impacts of Androgen Deprivation Therapy for Advanced Prostate Cancer
Ross A, Brewer K, Hudgens S, Brown B, Fallick M, de Paauw-Holt S, et al.
Adv Ther . 2024 Jun; 41(8):3076-3088. PMID: 38861216
Introduction: This qualitative research study was conducted to develop a novel, comprehensive, patient-reported outcome measure (PRO), the "Symptoms and Impacts of Androgen Deprivation Therapy (ADT) for Prostate Cancer" (SIADT-PC), assessing...
5.
[Special issue PRO] A demonstration of estimands and sensitivity analyses for time-to-deterioration of patient reported outcomes
Floden L, DeRosa M, Roydhouse J, Beaumont J, Hudgens S
J Biopharm Stat . 2024 Apr; :1-15. PMID: 38686622
In oncology trials, health-related quality of life (HRQoL), specifically patient-reported symptom burden and functional status, can support the interpretation of survival endpoints, such as progression-free survival. However, applying time-to-event endpoints...
6.
Meaningful Change Thresholds and Fatigue Severity Points on Patient-Reported Outcomes by the Fatigue Symptoms and Impacts Questionnaire in Patients With Relapsing Multiple Sclerosis
Hudgens S, Katz E, Davies E, Keenan A, Sidorenko T, Jamieson C
Value Health . 2024 Feb; 27(5):598-606. PMID: 38401796
Objectives: The Fatigue Symptoms and Impacts Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) is a new content-valid, concise, and reliable 20-item patient-reported outcome measure to evaluate the symptoms and impacts of fatigue in...
7.
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies
Hudgens S, Verstovsek S, Floden L, Harrison C, Palmer J, Gupta V, et al.
Value Health . 2024 Feb; 27(5):607-613. PMID: 38311180
Objectives: Patients with myelofibrosis develop symptoms due to bone marrow fibrosis, systemic inflammation, and/or organomegaly. Alleviating symptoms improves overall quality of life. Clinical trials have historically defined symptom response as...
8.
Quantitative and Qualitative Exploration of Meaningful Change on the Vineland Adaptive Behavior Scales (Vineland™-II) in Children and Adolescents with Autism Without Intellectual Disability Following Participation in a Clinical Trial
Clinch S, Hudgens S, Gibbons E, Willgoss T, Smith J, Polek E, et al.
Patient Relat Outcome Meas . 2023 Nov; 14:337-354. PMID: 38027418
Purpose: The Vineland Adaptive Behavior Scale is often used in autism spectrum disorder (ASD) trials. The Adaptive Behavior Composite Score (VABS-ABC) is the standardized overall score (the average of the...
9.
Establishing Meaningful Change Thresholds in Patient-Reported Outcomes Among Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in ALTA-1L Trial
Beaumont J, Lin H, Goodman E, Yu H, Geiger A, Hudgens S
Value Health . 2023 Nov; 27(2):182-189. PMID: 37951539
Objectives: An earlier study from the ALTA-1L trial of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer demonstrated that brigatinib produces superior health-related quality of life (QoL) outcomes over...
10.
Development and validation of a psoriasis treatment acceptability measure through group concept mapping
Hudgens S, Howerter A, Keith S, Evans C, Pelletier C
Health Qual Life Outcomes . 2023 Aug; 21(1):83. PMID: 37553594
Background: Psoriasis is a common autoimmune dermatologic condition which has a pronounced negative impact on patient quality of life and disease burden. Currently, there are a number of treatments available...